Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain

A potential biomarker of efficacy

Jennifer Y. Xie, Chaoling Qu, Amol M Patwardhan, Michael H. Ossipov, Edita Navratilova, Lino Becerra, David Borsook, Frank Porreca

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Preclinical assessment of pain has increasingly explored operant methods that may allow behavioral assessment of ongoing pain. In animals with incisional injury, peripheral nerve block produces conditioned place preference (CPP) and activates the mesolimbic dopaminergic reward pathway. We hypothesized that activation of this circuit could serve as a neurochemical output measure of relief of ongoing pain. Medications commonly used clinically, including gabapentin and nonsteroidal anti-inflammatory drugs (NSAIDs), were evaluated in models of post-surgical (1 day after incision) or neuropathic (14 days after spinal nerve ligation [SNL]) pain to determine whether the clinical efficacy profile of these drugs in these pain conditions was reflected by extracellular dopamine (DA) release in the nucleus accumbens (NAc) shell. Microdialysis was performed in awake rats. Basal DA levels were not significantly different between experimental groups, and no significant treatment effects were seen in sham-operated animals. Consistent with clinical observation, spinal clonidine produced CPP and produced a dose-related increase in net NAc DA release in SNL rats. Gabapentin, commonly used to treat neuropathic pain, produced increased NAc DA in rats with SNL but not in animals with incisional, injury. In contrast, ketorolac or naproxen produced increased NAc DA in animals with incisional but not neuropathic pain. Increased extracellular NAc DA release was consistent with CPP and was observed selectively with treatments commonly used clinically for post-surgical or neuropathic pain. Evaluation of NAc DA efflux in animal pain models may represent an objective neurochemical assay that may serve as a biomarker of efficacy for novel pain-relieving mechanisms.

Original languageEnglish (US)
Pages (from-to)1659-1666
Number of pages8
JournalPain
Volume155
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Reward
Nucleus Accumbens
Dopamine
Biomarkers
Pain
Neuralgia
Spinal Nerves
Ligation
Pain Measurement
Ketorolac
Anatomic Models
Naproxen
Nerve Block
Microdialysis
Wounds and Injuries
Clonidine
Pharmaceutical Preparations
Anti-Inflammatory Agents
Animal Models
Observation

Keywords

  • Biomarker
  • Dopamine
  • Neuropathic pain
  • Nucleus accumbens
  • Pain
  • Pain relief
  • Post-surgical pain
  • Rats

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine
  • Neurology
  • Pharmacology

Cite this

Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain : A potential biomarker of efficacy. / Xie, Jennifer Y.; Qu, Chaoling; Patwardhan, Amol M; Ossipov, Michael H.; Navratilova, Edita; Becerra, Lino; Borsook, David; Porreca, Frank.

In: Pain, Vol. 155, No. 8, 2014, p. 1659-1666.

Research output: Contribution to journalArticle

Xie, Jennifer Y. ; Qu, Chaoling ; Patwardhan, Amol M ; Ossipov, Michael H. ; Navratilova, Edita ; Becerra, Lino ; Borsook, David ; Porreca, Frank. / Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain : A potential biomarker of efficacy. In: Pain. 2014 ; Vol. 155, No. 8. pp. 1659-1666.
@article{7386cdfbdcc24faba10b2ebab8c1efae,
title = "Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: A potential biomarker of efficacy",
abstract = "Preclinical assessment of pain has increasingly explored operant methods that may allow behavioral assessment of ongoing pain. In animals with incisional injury, peripheral nerve block produces conditioned place preference (CPP) and activates the mesolimbic dopaminergic reward pathway. We hypothesized that activation of this circuit could serve as a neurochemical output measure of relief of ongoing pain. Medications commonly used clinically, including gabapentin and nonsteroidal anti-inflammatory drugs (NSAIDs), were evaluated in models of post-surgical (1 day after incision) or neuropathic (14 days after spinal nerve ligation [SNL]) pain to determine whether the clinical efficacy profile of these drugs in these pain conditions was reflected by extracellular dopamine (DA) release in the nucleus accumbens (NAc) shell. Microdialysis was performed in awake rats. Basal DA levels were not significantly different between experimental groups, and no significant treatment effects were seen in sham-operated animals. Consistent with clinical observation, spinal clonidine produced CPP and produced a dose-related increase in net NAc DA release in SNL rats. Gabapentin, commonly used to treat neuropathic pain, produced increased NAc DA in rats with SNL but not in animals with incisional, injury. In contrast, ketorolac or naproxen produced increased NAc DA in animals with incisional but not neuropathic pain. Increased extracellular NAc DA release was consistent with CPP and was observed selectively with treatments commonly used clinically for post-surgical or neuropathic pain. Evaluation of NAc DA efflux in animal pain models may represent an objective neurochemical assay that may serve as a biomarker of efficacy for novel pain-relieving mechanisms.",
keywords = "Biomarker, Dopamine, Neuropathic pain, Nucleus accumbens, Pain, Pain relief, Post-surgical pain, Rats",
author = "Xie, {Jennifer Y.} and Chaoling Qu and Patwardhan, {Amol M} and Ossipov, {Michael H.} and Edita Navratilova and Lino Becerra and David Borsook and Frank Porreca",
year = "2014",
doi = "10.1016/j.pain.2014.05.018",
language = "English (US)",
volume = "155",
pages = "1659--1666",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain

T2 - A potential biomarker of efficacy

AU - Xie, Jennifer Y.

AU - Qu, Chaoling

AU - Patwardhan, Amol M

AU - Ossipov, Michael H.

AU - Navratilova, Edita

AU - Becerra, Lino

AU - Borsook, David

AU - Porreca, Frank

PY - 2014

Y1 - 2014

N2 - Preclinical assessment of pain has increasingly explored operant methods that may allow behavioral assessment of ongoing pain. In animals with incisional injury, peripheral nerve block produces conditioned place preference (CPP) and activates the mesolimbic dopaminergic reward pathway. We hypothesized that activation of this circuit could serve as a neurochemical output measure of relief of ongoing pain. Medications commonly used clinically, including gabapentin and nonsteroidal anti-inflammatory drugs (NSAIDs), were evaluated in models of post-surgical (1 day after incision) or neuropathic (14 days after spinal nerve ligation [SNL]) pain to determine whether the clinical efficacy profile of these drugs in these pain conditions was reflected by extracellular dopamine (DA) release in the nucleus accumbens (NAc) shell. Microdialysis was performed in awake rats. Basal DA levels were not significantly different between experimental groups, and no significant treatment effects were seen in sham-operated animals. Consistent with clinical observation, spinal clonidine produced CPP and produced a dose-related increase in net NAc DA release in SNL rats. Gabapentin, commonly used to treat neuropathic pain, produced increased NAc DA in rats with SNL but not in animals with incisional, injury. In contrast, ketorolac or naproxen produced increased NAc DA in animals with incisional but not neuropathic pain. Increased extracellular NAc DA release was consistent with CPP and was observed selectively with treatments commonly used clinically for post-surgical or neuropathic pain. Evaluation of NAc DA efflux in animal pain models may represent an objective neurochemical assay that may serve as a biomarker of efficacy for novel pain-relieving mechanisms.

AB - Preclinical assessment of pain has increasingly explored operant methods that may allow behavioral assessment of ongoing pain. In animals with incisional injury, peripheral nerve block produces conditioned place preference (CPP) and activates the mesolimbic dopaminergic reward pathway. We hypothesized that activation of this circuit could serve as a neurochemical output measure of relief of ongoing pain. Medications commonly used clinically, including gabapentin and nonsteroidal anti-inflammatory drugs (NSAIDs), were evaluated in models of post-surgical (1 day after incision) or neuropathic (14 days after spinal nerve ligation [SNL]) pain to determine whether the clinical efficacy profile of these drugs in these pain conditions was reflected by extracellular dopamine (DA) release in the nucleus accumbens (NAc) shell. Microdialysis was performed in awake rats. Basal DA levels were not significantly different between experimental groups, and no significant treatment effects were seen in sham-operated animals. Consistent with clinical observation, spinal clonidine produced CPP and produced a dose-related increase in net NAc DA release in SNL rats. Gabapentin, commonly used to treat neuropathic pain, produced increased NAc DA in rats with SNL but not in animals with incisional, injury. In contrast, ketorolac or naproxen produced increased NAc DA in animals with incisional but not neuropathic pain. Increased extracellular NAc DA release was consistent with CPP and was observed selectively with treatments commonly used clinically for post-surgical or neuropathic pain. Evaluation of NAc DA efflux in animal pain models may represent an objective neurochemical assay that may serve as a biomarker of efficacy for novel pain-relieving mechanisms.

KW - Biomarker

KW - Dopamine

KW - Neuropathic pain

KW - Nucleus accumbens

KW - Pain

KW - Pain relief

KW - Post-surgical pain

KW - Rats

UR - http://www.scopus.com/inward/record.url?scp=84904621008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904621008&partnerID=8YFLogxK

U2 - 10.1016/j.pain.2014.05.018

DO - 10.1016/j.pain.2014.05.018

M3 - Article

VL - 155

SP - 1659

EP - 1666

JO - Pain

JF - Pain

SN - 0304-3959

IS - 8

ER -